Answers are grounded in this paper and cite their sources.
The introduction of CAR (chimeric antigen receptor) T-cell therapy into clinical practice has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM). At present, two B-cell maturation antigen (BCMA)-targeted CAR T-cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are used in clinical practice, but only ciltacabtagene autoleucel is approved in Brazil. In this review, we explore the advantages and challenges of integrating CAR T-cell therapy earlier in the RRMM treatment course.
No takes yet. Share an insight, caveat, or question.
Maiolino et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: